Mesoblast Limited share price today

Mesoblast Limited's share price was $14.29 at the close on 4 November 2026. It has been falling for 3 weeks. That is 7.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $12 and $21, and at that close it sat 23% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Mesoblast Limited is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 10 years the share price moved +73% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Mesoblast Limited pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Mesoblast Limited is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Mesoblast Limited posted a net loss of $17.3 M in the Jun 2026 quarter. The full FY26 year was a loss of $57.5 M. That loss is 25.2% of the quarter's revenue. The same quarter a year earlier lost $55.4 M. 12 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

Mesoblast Limited reported $68.9 M of revenue in the Jun 2026 quarter, +390.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 5 years it has grown 74.5% a year on average. The last full year, FY26, came in at $120 M.

Revenue is everything the company billed its customers in the period.

FY26 revenue was $120 M, +599.2% on the year before.

Recent pace: the last four quarters grew +592.3% on average, against 74.5% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +925.5%, against +179.1% a year over the last 8 quarters (accelerating).

Mesoblast Limited's operating margin was −33.3% in the Jun 2026 quarter, 269.1 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +1,215.2 percentage points. Across 6 years it has been between −1,196.1% and −42.6%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +1,215.2 percentage points on the year while gross margin changed +1,310.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Mesoblast Limited's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used $43.8 M of cash, against −$57.5 M of profit. After $833 K of spending on assets, free cash was −$44.7 M: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Mesoblast Limited does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.8 M on assets over the last 3 years. Averaged over those years that is 0.5% of FY26 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $1.8 M over the last 3 years.

In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it.

Mesoblast Limited has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Mesoblast Limited at 15.9× its FY26 revenue of $120 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Mesoblast Limited's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Mesoblast Limited earned a ROE of −10% in FY26. That is up from a low of −18% in FY22. Its return on capital used (ROIC) is 13.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a −47.8% net margin and 0.16× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −47.8% net margin × 0.16× asset turnover × 1.36× leverage (assets divided by equity) ≈ −10.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: −4.5% − 9.2% = −13.7 percentage points. The 9.2% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The −4.5% ROIC above is the latest reading, as reported. The yearly chart below shows FY21 at −16.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Mesoblast Limited has total debt of $127 M against shareholder equity of $568 M as of Jun 2026, so its debt is 0.22× its equity, which is very little. Year by year, that ratio went from 0.18 in FY21 to 0.22 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

We have no ownership or short-position figures for Mesoblast Limited, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 14.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

For Mesoblast Limited, the Z-score is 4.13. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.13 is well clear of the danger zone, so the balance sheet is not the risk here.

There is no score against its industry: Mesoblast Limited is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Mesoblast Limited is the 81st largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Maravai LifeSciences Holdings, Inc., Harmony Biosciences Holdings, Inc. and Vir Biotechnology, Inc. Just below it: Agios Pharmaceuticals, Inc., Zenas BioPharma, Inc. and Generate Biomedicines, Inc.

Biotechnology companies close in size

78. Maravai LifeSciences Holdings, Inc. $2 billion
79. Harmony Biosciences Holdings, Inc. $2 billion
80. Vir Biotechnology, Inc. $2 billion
81. Mesoblast Limited $1.9 billion
82. Agios Pharmaceuticals, Inc. $1.9 billion
83. Zenas BioPharma, Inc. $1.9 billion
84. Generate Biomedicines, Inc. $1.8 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

2022. Denison Mines Corp. $1.9 billion · Uranium
2023. Dime Commercial Bancshares, Inc. $1.9 billion · Banks - Regional
2024. Mesoblast Limited $1.9 billion
2025. German American Bancorp, Inc. $1.9 billion · Banks - Regional
2026. OceanFirst Financial Corp. $1.9 billion · Banks - Regional

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.